NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
NatureWise Biotech & Medicals Corporation (4732) - Net Assets
Latest net assets as of June 2025: NT$718.64 Million TWD
Based on the latest financial reports, NatureWise Biotech & Medicals Corporation (4732) has net assets worth NT$718.64 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$786.70 Million) and total liabilities (NT$68.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$718.64 Million |
| % of Total Assets | 91.35% |
| Annual Growth Rate | 11.02% |
| 5-Year Change | 30.96% |
| 10-Year Change | N/A |
| Growth Volatility | 34.68 |
NatureWise Biotech & Medicals Corporation - Net Assets Trend (2016–2024)
This chart illustrates how NatureWise Biotech & Medicals Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NatureWise Biotech & Medicals Corporation (2016–2024)
The table below shows the annual net assets of NatureWise Biotech & Medicals Corporation from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$783.56 Million | +23.67% |
| 2023-12-31 | NT$633.56 Million | -1.24% |
| 2022-12-31 | NT$641.51 Million | +2.75% |
| 2021-12-31 | NT$624.35 Million | +4.35% |
| 2020-12-31 | NT$598.31 Million | +12.31% |
| 2019-12-31 | NT$532.74 Million | +101.71% |
| 2018-12-31 | NT$264.11 Million | -5.34% |
| 2017-12-31 | NT$279.00 Million | -17.82% |
| 2016-12-31 | NT$339.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NatureWise Biotech & Medicals Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10041900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$40.41 Million | 5.45% |
| Common Stock | NT$493.67 Million | 66.62% |
| Other Comprehensive Income | NT$-860.00K | -0.12% |
| Other Components | NT$207.80 Million | 28.04% |
| Total Equity | NT$741.02 Million | 100.00% |
NatureWise Biotech & Medicals Corporation Competitors by Market Cap
The table below lists competitors of NatureWise Biotech & Medicals Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Hydrogen Corp
PINK:FHYDF
|
$19.42 Million |
|
CyberCatch Holdings Inc.
V:CYBE
|
$19.43 Million |
|
WIN HANVERKY
MU:N2R
|
$19.43 Million |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
$19.43 Million |
|
Alfabs Australia Ltd
AU:AAL
|
$19.42 Million |
|
Alpha Exploration Ltd
V:ALEX
|
$19.42 Million |
|
Soosung Innovation Co. Ltd.
KQ:084180
|
$19.41 Million |
|
BCWORLD PHARM. Co. Ltd
KQ:200780
|
$19.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NatureWise Biotech & Medicals Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 633,564,000 to 741,016,000, a change of 107,452,000 (17.0%).
- Net income of 897,000 contributed positively to equity growth.
- Dividend payments of 9,857,000 reduced retained earnings.
- New share issuances of 765,000 increased equity.
- Other comprehensive income decreased equity by 21,759,000.
- Other factors increased equity by 137,406,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$897.00K | +0.12% |
| Dividends Paid | NT$9.86 Million | -1.33% |
| Share Issuances | NT$765.00K | +0.1% |
| Other Comprehensive Income | NT$-21.76 Million | -2.94% |
| Other Changes | NT$137.41 Million | +18.54% |
| Total Change | NT$- | 16.96% |
Book Value vs Market Value Analysis
This analysis compares NatureWise Biotech & Medicals Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.20x to 1.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | NT$9.15 | NT$20.10 | x |
| 2017-12-31 | NT$7.52 | NT$20.10 | x |
| 2018-12-31 | NT$7.12 | NT$20.10 | x |
| 2019-12-31 | NT$14.09 | NT$20.10 | x |
| 2020-12-31 | NT$12.12 | NT$20.10 | x |
| 2021-12-31 | NT$12.66 | NT$20.10 | x |
| 2022-12-31 | NT$12.96 | NT$20.10 | x |
| 2023-12-31 | NT$12.70 | NT$20.10 | x |
| 2024-12-31 | NT$14.87 | NT$20.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NatureWise Biotech & Medicals Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.40%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.13x
- Recent ROE (0.12%) is above the historical average (-1.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -17.68% | -104.31% | 0.16x | 1.03x | NT$-93.96 Million |
| 2017 | -21.68% | -87.54% | 0.22x | 1.10x | NT$-88.39 Million |
| 2018 | -5.61% | -13.66% | 0.35x | 1.16x | NT$-41.23 Million |
| 2019 | 7.45% | 12.91% | 0.51x | 1.14x | NT$-13.58 Million |
| 2020 | 10.92% | 21.28% | 0.47x | 1.10x | NT$5.48 Million |
| 2021 | 4.93% | 12.33% | 0.35x | 1.13x | NT$-31.63 Million |
| 2022 | 4.68% | 13.13% | 0.33x | 1.08x | NT$-34.13 Million |
| 2023 | 1.60% | 6.32% | 0.23x | 1.10x | NT$-53.24 Million |
| 2024 | 0.12% | 0.40% | 0.27x | 1.13x | NT$-73.20 Million |
Industry Comparison
This section compares NatureWise Biotech & Medicals Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NatureWise Biotech & Medicals Corporation (4732) | NT$718.64 Million | -17.68% | 0.09x | $19.42 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |